Qualified Protein degradation is staying explored as a substitute approach in cancer, whereby the pure protein degradation process is co-opted for therapeutic applications. Not too long ago developed novel molecules known as proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules with two ligands joined by a linker. One ligand binds on the https://www.directivepublications.org/journal-of-clinical-breast-cancer/